Home Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting
 

Keywords :   


Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting

2016-04-19 20:05:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, is proud to be a part of the Blueprint PD-L1 Assay Comparison Project, an important initiative to compare several new diagnostic tests for the immune biomarker PD-L1 in non-small cell lung cancer (NSCLC). Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: research american project statement

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
24.11
24.11sobbat DB4R
24.11RC10
24.11 Knicks
24.11 W6S-JP001
24.11SALOMON XLT 150
24.11NU: EYE
24.11
More »